Detalles de la búsqueda
1.
Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D.
Liver Int
; 44(1): 139-147, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37787009
2.
Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial.
Liver Int
; 43(8): 1663-1676, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37183524
3.
A transient early HBV-DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction.
J Viral Hepat
; 28(2): 410-419, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33185325
4.
Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study.
Liver Int
; 41(2): 295-299, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33217778
5.
Direct-Acting Antiviral Use for Genotype 1b Hepatitis C Patients with Associated Hematological Disorders from Romania.
Medicina (Kaunas)
; 57(9)2021 Sep 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34577909
6.
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.
J Viral Hepat
; 26(6): 685-696, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30739368
7.
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
J Hepatol
; 64(1): 19-28, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26321288
8.
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials.
Hepatology
; 56(6): 2039-50, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22706730
9.
Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
Immunopharmacol Immunotoxicol
; 33(4): 744-50, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21320001
10.
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.
Lancet Infect Dis
; 19(3): 275-286, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30833068
11.
Comparison of the liver stiffness measurement by transient elastography with the liver biopsy.
World J Gastroenterol
; 14(42): 6513-7, 2008 Nov 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-19030204
12.
Real-Life Use of 3 Direct-Acting Antiviral Regimen in a Large Cohort of Patients with Genotype-1b HCV Compensated Cirrhosis.
J Gastrointestin Liver Dis
; 26(3): 275-281, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28922440
13.
Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study.
Ann Gastroenterol
; 30(3): 327-343, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28469364
14.
Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.
Medicine (Baltimore)
; 96(50): e9271, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29390377
15.
Chronic Kidney Disease--Chronic Liver Disease. An Immunologic Cross-talk.
Rom J Intern Med
; 53(1): 3-12, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26076555
16.
Hepatitis Delta Virus Infection in Romania: Prevalence and Risk Factors.
J Gastrointestin Liver Dis
; 24(4): 413-21, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26697566
17.
Are other factors besides albuminuria important for the progression of HCV chronic hepatitis towards CKD? A survey from a hepatology department in western Romania.
Rom J Intern Med
; 52(1): 13-7, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25000672
18.
Predictive value of FIB-4 and APRI versus METAVIR on sustained virologic response in genotype 1 hepatitis C patients.
Hepatol Int
; 8(1): 83-93, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26202409
19.
Anti-HDV IgM as a marker of disease activity in hepatitis delta.
PLoS One
; 9(7): e101002, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25072849
20.
Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.
J Gastrointestin Liver Dis
; 22(1): 27-32, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23539387